https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44958 MYCN oncogene amplification and consequent N-Myc oncoprotein over-expression die of the disease. Here our analyses of RNA sequencing data identify the long noncoding RNA lncNB1 as one of the transcripts most over-expressed in MYCN -amplified, compared with MYCN -non-amplified, human neuroblastoma cells and also the most over-expressed in neuroblastoma compared with all other cancers. lncNB1 binds to the ribosomal protein RPL35 to enhance E2F1 protein synthesis, leading to DEPDC1B gene transcription. The GTPase-activating protein DEPDC1B induces ERK protein phosphorylation and N-Myc protein stabilization. Importantly, lncNB1 knockdown abolishes neuroblastoma cell clonogenic capacity in vitro and leads to neuroblastoma tumor regression in mice, while high levels of lncNB1 and RPL35 in human neuroblastoma tissues predict poor patient prognosis. This study therefore identifies lncNB1 and its binding protein RPL35 as key factors for promoting E2F1 protein synthesis, N-Myc protein stability and N-Myc-driven oncogenesis, and as therapeutic targets.]]> Tue 25 Oct 2022 13:40:49 AEDT ]]> The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33114 Thu 24 Mar 2022 11:29:56 AEDT ]]> The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27851 Thu 17 Mar 2022 14:39:27 AEDT ]]> Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47275 Mon 27 Mar 2023 13:35:02 AEDT ]]>